Diabetes

Four poster presented at ENDO 2024 examined the current landscape of diabetes.

In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers addressed the association between social vulnerability and glycemic control in patients with diabetes.

Research presented at ENDO 2024 found that glucagon-like peptide-1 receptor agonists had a lower acute pancreatitis recurrence risk than SGLT2i, DPP4i, and no medication.

In an abstract presented at the Endocrine Society’s ENDO 2024 annual meeting in Boston, Massachusetts, researchers explored access to GLP-1s for teenagers with and without type 2 diabetes.

Higher serum testosterone concentration was not associated with a reduced risk of developing type 2 diabetes in men older than 65.

Semaglutide reduced the risk of major kidney disease and cardiovascular (CV) events, and death from any cause, while simultaneously decelerating the loss of kidney function, among patients with type 2 diabetes (T2D) and CKD compared to placebo.

A poster presented at Digestive Disease Week showed that patients with MASLD taking semaglutide achieved significant weight loss while preserving skeletal muscle indices.

Test your pharmacy news knowledge with our weekly quiz.

Efsitora (efsitora alfa) from Eli Lilly met its primary endpoint of non-inferior A1C reduction compared to insulin degludec and insulin glargine in 2 phase 3 studies.

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Researchers addressed the association of sleep quality and dietary intakes for patients with type 1 diabetes who use insulin pumps and continuous glucose monitoring.

Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.

With the judge’s failure to approve a settlement class, a $13.5 million settlement against Eli Lilly was called off.

A study from the Karolinska Institutet found that 76 out of 145410 patients treated with a GLP-1 developed thyroid cancer during nearly 4 years of follow-up.

After semaglutide and tirzepatide were approved, and ozempic use continues to rise, Medicare spending is also increasing because of a high demand for GLP-1 therapies.

Medication therapy management can also increase the likelihood of using statins in this population.

The latest guidelines advise managing obesity first, then treating a patient’s other conditions to produce optimal outcomes.

See what's trending in pharmacy with a preview the Drug Topics March issue.

The implementation of targeted educational interventions might improve knowledge gaps, which pose great risk to patients, in type 2 diabetes (T2D) management.

Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.

If approved, KnowU will become the world’s first non-invasive blood glucose monitor introduced to the global marketplace.

As acute and chronic diabetes complications increase, particularly among younger and socioeconomically disadvantaged populations, out-of-pocket costs remain a barrier to accessing essential medications.

Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).

A new study found that over a quarter of participants with type 1 daiebets exhibited clinically relevant levels of posttraumatic stress symptoms related to a diabetes event that they experienced.

Although diabetes mortality rates were stable in the Americas over the past 2 decades, the actual number of diabetes-related deaths is rising.